Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial

Gilbert Bensimon, Massimo Locati, Hang‐Phuong Pham et al.|The Lancet|2025

Cited by 33